Clinical Scorecard: Characterization of Unique Clinical and Pathogenic Subgroups in Pediatric Lyme Neuroborreliosis

At a Glance

Key Highlights

• LNB presents with a broad clinical spectrum in children, most commonly meningitis (60.5%) and isolated cranial neuropathy (28.9%).
• Distinct clinico-pathogenic subgroups identified: isolated cranial neuropathy (localized PNS disease) vs meningitis/meningoradiculitis (systemic PNS and CNS involvement).
• Diagnosis relies on neurological symptoms, CSF pleocytosis, and intrathecal B burgdorferi-specific antibody production, though early diagnosis is challenging due to delayed antibody detection.

Guideline-Based Recommendations

Diagnosis

• Diagnosis requires neurological symptoms/signs plus positive 2-tier serology in blood or CSF and/or intrathecal antibody production.
• Definite LNB diagnosis requires neurological symptoms, CSF pleocytosis, and intrathecal B burgdorferi-specific antibodies.
• Possible LNB diagnosis requires two of the three criteria, with serum antibodies after 6 weeks if intrathecal antibodies are absent.

Management

• Clinical subgroup classification (iCN, meningitis, meningoradiculitis) may guide management and prognosis.
• Recognition of severe CNS manifestations (myelitis, cerebral vasculitis) is important despite rarity.

Monitoring & Follow-up

• Monitor symptom duration post-treatment, noting shorter duration in isolated cranial neuropathy subgroup.
• Follow-up CSF and serological testing may support diagnosis and treatment response.

Risks

• Delayed diagnosis due to early absence of detectable B burgdorferi-specific antibodies.
• Rare but severe CNS complications including myelitis and cerebral vasculitis.

Patient & Prescribing Data

Children diagnosed with Lyme neuroborreliosis at a tertiary pediatric center

Isolated cranial neuropathy subgroup shows weaker antibody responses and shorter post-treatment symptom duration compared to meningitis or meningoradiculitis subgroups

Clinical Best Practices

• Consider LNB in children presenting with facial palsy and/or meningitis symptoms in endemic areas.
• Use combined clinical, CSF, and serological criteria for accurate diagnosis, recognizing limitations in early antibody detection.
• Classify patients into clinical subgroups to tailor prognosis and management strategies.
• Be vigilant for rare severe CNS manifestations requiring specialized care.

References

• European Federation of Neurological Societies (EFNS) Guidelines on Lyme Neuroborreliosis
• Lyme Disease Epidemiology and Clinical Features
• Diagnostic Criteria and Immunological Characterization of Pediatric LNB